Village Neuf

Researchers are conducting ALZEVIT, a large, nationwide, decentralized observational study in France focused on Alzheimers disease AD prevention. This study aims to create a large-scale Apolipoprotein E APOE genotyping registry and enable precision prevention strategies, especially targeting people at high genetic risk like APOE 4 carriers and homozygotes. It addresses the need for early detection of individuals at risk to support emerging disease-modifying therapies most effective in early or preclinical stages. Participants aged 45 and older enroll online, provide electronic consent, and self-collect saliva samples at home using a provided kit for centralized APOE genotyping. Phase A first 18 months will enroll 50,000 participants to determine APOE genotype distribution and evaluate large-scale digital genetic screening feasibility with ongoing online cognitive and risk factor assessments. Phase B months 12-24 involves detailed testing of about 2,350 participants representing all APOE genotypes, including clinical evaluations, MRI scans, cognitive tests, and advanced biomarker profiling conducted at memory centers or via telemedicine. Participants provide self-reported health, lifestyle, and cognitive information through questionnaires and complete validated cognitive assessments over time. Researchers collect biosamples for multi-omics analyses and classify participants along the cognitive spectrum from normal to mild or moderate AD. The study monitors cognitive changes, biomarker evolution, and risk or resilience factors to better understand APOE-related disease pathways. Data are securely stored under GDPR, supporting future prevention trials and precision medicine approaches for Alzheimers disease.

This research aims to validate the stability of various diagnostic biomarkers measured by Firalis IVD tests in healthy volunteers. The study focuses on biomarkers such as long non-coding RNAs lncRNAs, small non-coding RNAs sncRNAs, messenger RNAs mRNAs, proteins, lipids, and metabolites, also examining the effects of gender, age, and nutrition on these markers. Firalis SA and its affiliate Amoneta Diagnostics SAS are developing these tests for major diseases including cardiovascular and neurodegenerative disorders, supporting the analytical validation phase of their diagnostic tools. Participants in this study will undergo biomarker-based in-vitro diagnostic IVD tests developed by Firalis. The tests involve collecting biological samples to analyze the expression levels of these biomarkers under different conditions, such as before and after breakfast intake. This study includes a single group of healthy volunteers, and the focus is on stability and expression level assessments rather than treatment or intervention. The study does not involve medication or placebo but collects data to support diagnostic test validation. During the study, participants will provide biological samples at baseline fasting, before breakfast and then again one hour after breakfast to measure biomarker expression. Researchers will analyze the expression of lncRNAs, sncRNAs, mRNAs, and soluble proteins at these timepoints. The study also considers factors like age, gender, nutrition, and time intervals between sample collections. Participant involvement includes signing informed consent, complying with study procedures, and attending scheduled sample collection visits. The study duration extends until April 2027, with the primary outcome measured by biomarker expression changes before and after breakfast.